ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0487

The Triglyceride to HDL Ratio, a Surrogate Marker of Insulin Resistance, Predicts All Cause and Cardiovascular Mortality in Rheumatoid Arthritis

Jose Felix Restrepo Suarez1, Carlos Lorenzo1, Inmaculada Del rincon2 and Agustin Escalante1, 1UT Health San Antonio, San Antonio, TX, 2UT Health San Antonio, San Antonio

Meeting: ACR Convergence 2024

Keywords: Cardiovascular, Mortality, rheumatoid arthritis, risk factors

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 16, 2024

Title: RA – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: The triglyceride to HDL cholesterol (TG/HDL) ratio, a recognized surrogate marker of insulin resistance, has emerged as a predictor of cardiovascular (CV) risk. However, its clinical relevance in RA remains unexplored. In this study, we aimed to investigate the prognostic value of the TG/HDL ratio in predicting mortality in RA patients.

Methods: RA patients meeting the 1987 ACR criteria were recruited consecutively from rheumatology practices from 1996 to 2011. Patients were invited to return for periodic follow-up evaluations. At each visit, clinical and laboratory variables were recorded, including measures of RA disease activity, CV risk factors and the occurrence of CV events. All deaths were confirmed with a death certificate. Deaths were classified as having a CV cause if the death certificate included conditions with ICD-9 codes 390-459.

We used logistic regression analysis to examine the association between TG/HDL ratio and all-cause and CV mortality. Results were adjusted for other risk factors including age, sex, smoking status, diabetes, hypertension, and disease activity (measured by DAS28 ESR).

Results: We studied 1211 patients [906 (75%) were women]. The mean follow-up time was 9.959 person-years with 278 deaths (2.7 per 100 person-years) for all-cause mortality. The mean follow-up time for CV mortality was 8745 person-years with 121 deaths (0.3 per 100 person-years).

TG/HDL ratio was associated with an increased risk of both all-cause mortality (OR=1.09, 95% CI 1.00-1.19, p=0.041) (Table 1) and CV mortality (OR=1.21, 95% CI 1.09-1.35, p< 0.001). (Table 2) after adjusting for age, sex, disease activity, diabetes, smoking status, and hypertension.

Conclusion: TG/HDL ratio is an independent risk factor of all cause and CV mortality in RA patients. These findings suggest that the TG/HDL ratio may be a useful biomarker for assessing CV risk among patients with RA, which could lead to improved risk management and reduced CV morbidity and mortality among RA patients. The role of insulin resistance in RA deserves further study.

Supporting image 1

Supporting image 2


Disclosures: J. Restrepo Suarez: None; C. Lorenzo: None; I. Del rincon: None; A. Escalante: None.

To cite this abstract in AMA style:

Restrepo Suarez J, Lorenzo C, Del rincon I, Escalante A. The Triglyceride to HDL Ratio, a Surrogate Marker of Insulin Resistance, Predicts All Cause and Cardiovascular Mortality in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/the-triglyceride-to-hdl-ratio-a-surrogate-marker-of-insulin-resistance-predicts-all-cause-and-cardiovascular-mortality-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-triglyceride-to-hdl-ratio-a-surrogate-marker-of-insulin-resistance-predicts-all-cause-and-cardiovascular-mortality-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology